Johanna Bendell, MD

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the importance of testing CRC patients for BRAF status.

Johanna Bendell, MD, Director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the results of a randomized, double-blind, multicenter phase II trial that examined FOLFOX with or without ramucirumab as front-line therapy for advanced gastric or esophageal adenocarcinoma.